The state of COPD

COPD is a highly debilitating and often fatal lung disease, and is one of the leading causes of death worldwide.

The state of COPD

Context

Chronic obstructive pulmonary disease (COPD) deteriorates lung function – it restricts airflow and makes breathing increasingly difficult, potentially affecting every facet of a person’s life.

Recent data suggest there are up to 391 million people currently living with COPD around the world. Every hour, some 425 people die of COPD – and, in low- and middle-income countries, 90% of COPD deaths occur in people younger than 70.

People of lower socioeconomic position are at higher risk of developing COPD. This is due to factors such as exposure to household and outdoor air pollutants, poor nutrition, infections and smoking tobacco.

COPD is the seventh leading cause of poor health worldwide. Its symptoms gradually worsen and manifest as flare-ups which, when severe, require emergency hospital admission. More than one in five people die within one year of being hospitalised for a COPD flare-up. Living with COPD can curtail a person’s independence, impact their relationships with friends and family, and even force them to give up their jobs: around 40% of people with COPD have to reduce or stop working altogether.

The pressure COPD places on health systems is unsustainable. It is a leading cause of hospital admissions in many countries. Without investment in evidence-based interventions, COPD is predicted to cost the global economy INT $4.3 trillion between 2020 and 2050.

These costs could be reduced if health systems were to move from reactive to proactive strategies, with all people receiving earlier diagnosis and guideline-recommended care. It is vital to enhance awareness and prioritisation of COPD among health system decision-makers, to catalyse change that will improve both health outcomes and, ultimately, people’s lives.

What we’ve achieved

The Health Policy Partnership worked with the Speak Up for COPD coalition, respiratory experts and people living with COPD around the world to shed light on current responses to COPD and highlight opportunities for policy action and system change by showcasing promising initiatives that are already taking place. Desk research and interviews led to the development of a global report and infographic.

In 2023, HPP developed the short ‘Why Speak Up for COPD?’ video featuring four key stakeholders representing advocacy, clinical and policymaking expertise. The video is available with subtitles in English, French, German and Spanish.

The global report and infographic were launched at the 2024 GAAPP Summit in Vienna ahead of the European Respiratory Society Congress. We presented key findings of the state of COPD project to patient advocates from around the world, to help them make best use of these resources for their local contexts.

Key partners and stakeholders

This project was developed with the support of the following partners and stakeholders:

  • Dr Bamidele Olaiya Adeniyi, Isle of Wight NHS Trust; formerly Federal Medical Centre, Owo, Nigeria
  • Mohit Bhutani, University of Alberta, Canada
  • Professor Joanna Chorostowska-Wynimko, Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Poland
  • Chunhua Chi, Peking University First Hospital; General Practice Development Research Center, Peking University Health Science Center; and the Chinese Alliance for Respiratory Disease in Primary Care, China
  • Peter Deussen, NIHR Oxford Biomedical Research Centre (Patient & Public Involvement member), United Kingdom
  • Suzanne Edmonds, COPD Canada, Canada
  • Gregory Erhabor, Department of Medicine, Obafemi Awolowo University, Ile-Ife, Nigeria
  • Dr Frederico Fernandes, Brazilian Respiratory Society, Brazil
  • Rita Ferraz, a person with COPD, Brazil
  • Mohammed Al Ghobain, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia
  • Dr Angela Honda, ProAR Foundation, Brazil
  • John Hurst, University College London, United Kingdom

We would also like to thank a carer for a person with COPD in China, who asked to remain anonymous.

The Speak Up for COPD coalition includes the Global Allergy & Airways Patient Platform, International Federation of Ageing, COPD Foundation, International Coalition of Respiratory Nurses, International Pharmaceutical Federation, with funding from AstraZeneca, Roche, Sanofi and Regeneron.

  • Dr Ahmad Izuanuddin Ismail, Faculty of Medicine, Universiti Teknologi MARA & Malaysian Thoracic Society, Malaysia
  • Christine Jenkins, The George Institute for Global Health and UNSW Sydney, Australia
  • Honorary Prof. Ee Ming Khoo, Faculty of Medicine, Universiti Malaya, Malaysia
  • Dr Riyad Al-Lehebi, King Fahad Medical City, Riyadh
  • Dr Christopher Licskai, Western University
  • Dr Eric Marchand, Head of the Department of Pneumology, CHU-UCL-Namur, Godinne; Belgian Respiratory Society COPD Work Group, Belgium
  • Victor Nevelsteen, Vlaamse COPD Vereniging, Belgium
  • Uchenna Ogbonnia, Asthma Relief Campaign Project, Nigeria
  • Dr Rudi Peché, CHU Charleroi, Belgium
  • Ravijyot Saggu, Chair for UK Clinical Pharmacy Association Respiratory Committee, United Kingdom
  • Gitta Vanpeborgh, former Member of the Chamber of Representatives of Belgium
  • Tom Wilkinson, University of Southampton and National Respiratory Audit Programme, United Kingdom
  • Russell Winwood, a person with COPD, Australia

Project funding

HPP was commissioned by the Speak Up for COPD coalition. Speak Up for COPD is supported by a coalition of partners across the non-profit sector and pharmaceutical industry to establish COPD as a public health priority. Funding is provided by pharmaceutical industry partners. All partners contributed to this project.

Share